Journal
CANCER TREATMENT REVIEWS
Volume 48, Issue -, Pages 34-41Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2016.06.004
Keywords
BRCAness; Carboplatin; Cisplatin; Triple negative breast cancer
Categories
Ask authors/readers for more resources
Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment options and poor prognosis once metastatic. Pre-clinical and clinical data suggest that TNBC could be more sensitive to platinum-based chemotherapy, especially among BRCA1/2-mutated patients. In recent years, several randomised trials have been conducted to evaluate platinum efficacy in both early-stage and advanced TNBC, with conflicting results especially for long-term outcomes. Experimental studies are now focusing on identifying biomarkers of response to help selecting patients who may benefit most from platinum based therapies, including BRCA1/2 mutational status and genomic instability signatures (such as HRD-LOH or HRD-LST scores). A standard therapy for TNBC is still missing and platinum-based regimens represent an emerging therapeutic option for selected patients with a defect in the homologous recombination repair system: The identification of these patients through validated biomarker assays will be crucial to optimize the use of currently approved agents in TNBC. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available